AC IMMUNE SA (ACIU)

CH0329023102 - Common Stock

4.05  -0.04 (-0.98%)

After market: 4.13 +0.08 (+1.98%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

AC IMMUNE SA

NASDAQ:ACIU (6/21/2024, 7:00:00 PM)

After market: 4.13 +0.08 (+1.98%)

4.05

-0.04 (-0.98%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustry
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%
Sales Q2Q%
CRS
6 Month-6.47%
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap401.76M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ACIU Daily chart

Company Profile

AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. The company is headquartered in Lausanne, Vaud and currently employs 126 full-time employees. The company went IPO on 2016-09-23. The firm focuses on precision medicine for neurodegenerative diseases. The company designs, discovers and develops therapeutic, as well as diagnostic products for prevention, diagnosis and treatment of diseases caused by misfolding proteins. Its SupraAntigen and Morphomer technology platforms to create antibodies, small molecules and vaccines designed to address a broad range of neurodegenerative indications, such as Alzheimer's disease (AD). The firm's pipeline includes nine therapeutic product candidates with five in clinical trials, and three diagnostic candidates. Its lead product candidate is Crenezumab, a humanized and monoclonal anti-Abeta antibody for Alzheimer’s disease. The company has collaborations with pharmaceutical companies, including Roche/Genentech, Eli Lilly, Biogen, Janssen Pharmaceuticals, Nestle Institute of Health Sciences, Life Molecular Imaging (formerly Piramal Imaging) and Essex Bio-Technology.

Company Info

AC IMMUNE SA

EPFL Innovation Park, Building B

Lausanne VAUD 1015

P: 41213459121

CEO: Andrea Pfeifer

Employees: 126

Website: https://www.acimmune.com/

ACIU News

News Image25 days ago - AC Immune SAAC Immune to Present at the Jefferies Global Healthcare Conference in June 2024
News Image25 days ago - AC Immune SAAC Immune to Present at the Jefferies Global Healthcare Conference in June 2024

AC Immune to Present at the Jefferies Global Healthcare Conference in June 2024 Lausanne, Switzerland, May 28, 2023 – AC Immune SA (NASDAQ: ACIU), a...

News Imagea month ago - InvestorPlaceACIU Stock Earnings: AC Immune Misses EPS for Q1 2024

ACIU stock results show that AC Immune missed analyst estimates for earnings per share the first quarter of 2024.

News Imagea month ago - InvestorPlaceWhy Is TransCode Therapeutics (RNAZ) Stock Down 14% Today?

TransCode Therapeutics stock is down on Monday after the company announced plans for a shareholder meeting for RNAZ investors.

News Imagea month ago - InvestorPlaceWhy Is Safe & Green Development (SGD) Stock Down 5% Today?

Safe & Green Development stock is down on Monday as SGD investors learn of a Form D filing with the SEC for a securities sale.

News Imagea month ago - InvestorPlaceWhy Is AC Immune (ACIU) Stock Up 45% Today?

AC Immune stock is up on Monday after as investors in ACIU react to a new collaboration agreement with Takeda Pharmaceutical.

ACIU Twits

Here you can normally see the latest stock twits on ACIU, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example